| The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial 2022 · Quercetin · Adults over 18 hospitalized in a non-ICU ward with severe COVID-19 | 1 g | 7 days | 30 |
| Quercetin reduces illness but not immune perturbations after intensive exercise 2007 · quercetin · trained male cyclists; age and health condition not specified | 1 g | 3 weeks | 20 |
| The Adjunctive Effect of Quercetin on Postoperative Pain Management Following Cesarean Section: A Randomized Controlled Study 2025 · Quercetin group · Pregnant females over 18 years undergoing elective full-term cesarean section under spinal anesthesia | 500 mg | 1 day | 40 |
| The Effect of Quercetin on Inflammatory Factors and Clinical Symptoms in Women with Rheumatoid Arthritis: A Double-Blind, Randomized Controlled Trial 2017 · quercetin group · Women with rheumatoid arthritis | 500 mg | 8 weeks | — |
| Quercetin's influence on exercise performance and muscle mitochondrial biogenesis 2010 · quercetin (Q) · Untrained young adult males, mean age 20.2 years | 1 g | 2 weeks | 26 |
| Quercetin Supplementation Improves Neuromuscular Function Recovery from Muscle Damage 2020 · Q supplementation · Healthy men, mean age 25.9 ± 3.3 years, without reported cardiac, metabolic, neurological or renal disease; low-to-moderate physical activity | 1 g | 2 weeks | 16 |
| Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial 1999 · quercetin · Men with category IIIa or IIIb chronic pelvic pain syndrome | 1 g | 30 days | 15 |
| The effect of quercetin and citrulline on cycling time trial performance 2024 · QCT · Male and female trained, regularly competing cyclists aged 18–55 years | 1 g | 4 weeks | 13 |
| The Effects of Quercetin Supplementation on Eccentric Exercise-Induced Muscle Damage 2019 · Quercetin (Q) treatment · Moderately active men aged 26.1 ± 3.1 years undergoing an eccentric exercise protocol; no diagnosed condition reported | 1 g | 2 weeks | 12 |
| The acute effect of Quercetin on muscle performance following a single resistance training session 2018 · Quercetin · Young men, mean age 22.1 years; no diagnosed condition stated | 1 g | 1 day | 10 |
| Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease 2020 · 500 mg/day quercetin group · Adults aged 40–80 years with mild-to-moderate COPD and a smoking history of at least 10 pack-years | 500 mg | 7 days | 2 |
| The dietary flavonoid quercetin increases VO(2max) and endurance capacity 2010 · quercetin · healthy, untrained volunteers | 1 g | 7 days | — |
| A polycentric, randomized, parallel-group, study on Lertal®, a multicomponent nutraceutical, as preventive treatment in children with allergic rhinoconjunctivitis: phase II 2019 · Lertal® Group (LG) · Children aged 6–12 years with allergic rhinoconjunctivitis and sensitization to house dust mites or pollens | 150 mg | 12 weeks | 64 |
| Effect of quercetin on traits of the metabolic syndrome, endothelial function and inflammation in men with different APOE isoforms 2013 · quercetin · healthy men with APOE genotypes 3/3, 3/4 or 4/4 | 150 mg | 8 weeks | 49 |
| Effect of onion peel extract on endothelial function and endothelial progenitor cells in overweight and obese individuals 2015 · OPE group · Healthy overweight and obese individuals | 100 mg | 12 weeks | 36 |
| Enzymatically modified isoquercitrin improves endothelial function in volunteers at risk of cardiovascular disease 2020 · EMIQ® · Adults with at least one cardiovascular disease risk factor; 12 males and 13 females, ages not reported | 2 mg/kg | 1 day | 25 |
| Quercetin ingestion alters motor unit behavior and enhances improvement in muscle strength following resistance training in older adults: a randomized, double-blind, controlled trial 2025 · quercetin (QUE) group · Healthy, physically independent adults aged 65–82 years, male and female | 200 mg | 6 weeks | 13 |
| The effect of quercetin and citrulline on cycling time trial performance 2024 · QCT+CIT · Male and female trained, regularly competing cyclists aged 18–55 years | 1 g | 4 weeks | 12 |
| Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease 2020 · 1000 mg/day quercetin group · Adults aged 40–80 years with mild-to-moderate COPD and a smoking history of at least 10 pack-years | 1 g | 7 days | 2 |
| Effect of enzymatically modified isoquercitrin, a flavonoid, on symptoms of Japanese cedar pollinosis: a randomized double-blind placebo-controlled trial 2009 · EMIQ group · People with Japanese cedar pollinosis; age and sex not specified | 200 mg | 8 weeks | — |
| Preventative effect of a flavonoid, enzymatically modified isoquercitrin on ocular symptoms of Japanese cedar pollinosis 2009 · EMIQ group · People with Japanese cedar pollinosis; age and sex not reported | 100 mg | 8 weeks | — |
| Effects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study 2022 · quercetin-containing supplement group · Japanese adults aged 22–78 with allergic symptoms of pollinosis | 200 mg | 4 weeks | — |
| Effects of 7-day quercetin intervention on motor unit activity and muscle contractile properties before and after resistance exercise in young adults randomized controlled trials 2024 · quercetin glycosides (QUE) · young adult men and women; no specific condition stated | 200 mg | 7 days | — |
| Quercetin reduces blood pressure in hypertensive subjects 2007 · quercetin · Men and women with prehypertension or stage 1 hypertension | 730 mg | 4 weeks | 41 |
| Aloysia citriodora Palau (lemon verbena) for insomnia patients: A randomized, double-blind, placebo-controlled clinical trial of efficacy and safety 2019 · A. citriodora group · People with insomnia; age and sex not specified | 3.22 mg | 4 weeks | 50 |
| Effects of a Singular Dose of Mangiferin-Quercetin Supplementation on Basketball Performance: A Double-Blind Crossover Study of High-Level Male Players 2024 · EXP group, POST condition (mangiferin–quercetin) · Highly trained/national-level male basketball players aged over 18 years, representing the top three Greek national leagues | 140 mg | 1 day | 19 |
| Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease 2020 · 2000 mg/day quercetin group · Adults aged 40–80 years with mild-to-moderate COPD and a smoking history of at least 10 pack-years | 2 g | 7 days | 2 |
| Effect of a dietary supplement containing glucosamine hydrochloride, chondroitin sulfate and quercetin glycosides on symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled study 2012 · GCQ supplement · Japanese subjects with symptomatic knee osteoarthritis | 45 mg | 16 weeks | — |
| The Impact of Decaffeinated Green Tea Extract on Fat Oxidation, Body Composition and Cardio-Metabolic Health in Overweight, Recreationally Active Individuals 2021 · dGTE+ · Adults over 18 who were recreationally active and overweight (BMI 25.0–29.9 kg/m² and/or body fat in the overweight category); healthy, without the listed cardio-metabolic or blood/liver disorders | 50 mg | 8 weeks | — |
| Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study 2009 · quercetin treatment · Overweight or obese adults aged 25–65 years with metabolic syndrome traits | 150 mg | 6 weeks | 93 |
| Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype 2010 · quercetin · Overweight-obese volunteers aged 25–65 years with metabolic syndrome traits; apoE3 and apoE4 subgroups were analyzed | 150 mg | 6 weeks | 93 |
| Effects of a quercetin-rich onion skin extract on 24 h ambulatory blood pressure and endothelial function in overweight-to-obese patients with (pre-)hypertension: a randomised double-blinded placebo-controlled cross-over trial 2015 · quercetin · Adults aged 25–65 years with overweight or obesity and pre-hypertension or stage I hypertension, with metabolic-syndrome traits | 162 mg | 6 weeks | 70 |
| Acute, quercetin-induced reductions in blood pressure in hypertensive individuals are not secondary to lower plasma angiotensin-converting enzyme activity or endothelin-1: nitric oxide 2012 · quercetin · men: normotensive men aged 24 ± 3 years and men with stage 1 hypertension aged 41 ± 12 years | 1.1 g | 1 day | 17 |
| Improved Oral Absorption of Quercetin from Quercetin Phytosome®, a New Delivery System Based on Food Grade Lecithin 2019 · Treatment A (quercetin 500 mg) · Healthy adults aged 18–50 years, both sexes, without significant organic or psychiatric disease | 500 mg | 1 day | 12 |
| Improved Oral Absorption of Quercetin from Quercetin Phytosome®, a New Delivery System Based on Food Grade Lecithin 2019 · Treatment B (Quercetin Phytosome 500 mg) · Healthy adults aged 18–50 years, both sexes, without significant organic or psychiatric disease | 500 mg | 1 day | 12 |
| Comparison of quercetin pharmacokinetics following oral supplementation in humans 2012 · quercetin suspension · 18 healthy adults; sex and age not reported | 500 mg | 1 day | 6 |
| Comparison of quercetin pharmacokinetics following oral supplementation in humans 2012 · First Strike nutritional bars · 18 healthy adults; sex and age not reported | 500 mg | 1 day | 6 |
| Comparison of quercetin pharmacokinetics following oral supplementation in humans 2012 · RealFX Q-Plus chews · 18 healthy adults; sex and age not reported | 500 mg | 1 day | 6 |
| The variable plasma quercetin response to 12-week quercetin supplementation in humans 2010 · Q-500 · Adults aged 18–85 recruited from the community | 500 mg | 12 weeks | — |
| Glucosamine-containing supplement improves locomotor functions in subjects with knee pain: a randomized, double-blind, placebo-controlled study 2015 · GCQID group · Japanese women and men aged 40–74 years with knee pain | 90 mg | 16 weeks | 50 |
| Acute Ingestion of a Mixed Flavonoid and Caffeine Supplement Increases Energy Expenditure and Fat Oxidation in Adult Women: A Randomized, Crossover Clinical Trial 2019 · Mixed flavonoid-caffeine (MFC) supplement · Healthy premenopausal women aged 20–47 years | 208 mg | 1 day | 19 |
| Effects of quercetin supplementation on inflammatory factors and quality of life in post-myocardial infarction patients: A double blind, placebo-controlled, randomized clinical trial 2021 · quercetin group · post-myocardial infarction patients; age and sex not stated | 500 mg | 8 weeks | 44 |
| The effect of quercetin on iron overload and inflammation in β-thalassemia major patients: A double-blind randomized clinical trial 2019 · quercetin group · Patients with β-thalassemia major; age and sex not stated | 500 mg | 12 weeks | 42 |
| Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer 2019 · cohort A · Adults with advanced cancer at high risk for thrombosis; age and sex not specified | 500 mg | 8 weeks | 28 |
| Quercetin lowers plasma uric acid in pre-hyperuricaemic males: a randomised, double-blinded, placebo-controlled, cross-over trial 2016 · quercetin · healthy males aged 19–60 years with baseline plasma uric acid in the higher but healthy range | 500 mg | 4 weeks | 22 |
| Effect of quercetin on CYP3A activity in Chinese healthy participants 2012 · quercetin · healthy male volunteers; age not reported | 500 mg | 13 days | 18 |
| Effect of quercetin on P-glycoprotein transport ability in Chinese healthy subjects 2013 · quercetin · Healthy Chinese adults with different MDR1 3435 C/T genotypes | 500 mg | 13 days | 18 |
| Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment 2012 · quercetin capsules · healthy Chinese-Han male volunteers | 500 mg | 2 weeks | — |
| Quercetin and polycystic ovary syndrome; inflammation, hormonal parameters and pregnancy outcome: A randomized clinical trial 2023 · quercetin group · Women with polycystic ovary syndrome undergoing IVF | 500 mg | 40 days | — |
| Quercetins efficacy on bone and inflammatory markers, body composition, and physical function in postmenopausal women 2025 · 500 mg of quercetin (QUE) once daily · Healthy postmenopausal women | 500 mg | 90 days | — |
| Effect of alpha-linolenic acid in combination with the flavonol quercetin on markers of cardiovascular disease risk in healthy, non-obese adults: A randomized, double-blinded placebo-controlled crossover trial 2019 · ALA plus quercetin · Healthy, non-obese men and women; mean age 24.6 years | 190 mg | 8 weeks | — |
| Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial 2010 · Q-500 · Men and women aged 18–85 from the community, including people with and without chronic disease | 500 mg | 12 weeks | 334 |
| Improved Oral Absorption of Quercetin from Quercetin Phytosome®, a New Delivery System Based on Food Grade Lecithin 2019 · Treatment C (Quercetin Phytosome 250 mg) · Healthy adults aged 18–50 years, both sexes, without significant organic or psychiatric disease | 250 mg | 1 day | 12 |
| The variable plasma quercetin response to 12-week quercetin supplementation in humans 2010 · Q-1000 · Adults aged 18–85 recruited from the community | 1 g | 12 weeks | — |
| Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients 2025 · quercetin supplementation · Adults aged 18 years or older, men and women, with recent acute coronary syndrome undergoing coronary artery bypass graft surgery | 1 g | 9 days | 47 |
| Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer 2019 · cohort B · Adults with advanced cancer at high risk for thrombosis; age and sex not specified | 1 g | 8 weeks | 29 |
| Consumption of high doses of chlorogenic acid, present in coffee, or of black tea increases plasma total homocysteine concentrations in humans 2001 · quercetin-3-rutinoside · Healthy men and women; age not stated | 440 mg | 7 days | 20 |
| Quercetin's influence on exercise-induced changes in plasma cytokines and muscle and leukocyte cytokine mRNA 2007 · quercetin (Q) · trained male cyclists | 1 g | 24 days | 20 |
| The flavonoid quercetin induces acute vasodilator effects in healthy volunteers: correlation with beta-glucuronidase activity 2014 · 400 mg quercetin · Healthy volunteers, mean age 26±5 years, including women and men | 400 mg | 1 day | 15 |
| Chronic consumption of quercetin reduces erythrocytes oxidative damage: Evaluation at resting and after eccentric exercise in humans 2018 · quercetin · healthy individuals undergoing eccentric exercise | 1 g | 2 weeks | 14 |
| Quercetin Modulates IGF-I and IGF-II Levels After Eccentric Exercise-Induced Muscle-Damage: A Placebo-Controlled Study 2021 · quercetin (Q) treatment · Healthy moderately active men aged 18–30 | 1 g | 2 weeks | 12 |
| Effects of Quercetin on Adiponectin-Mediated Insulin Sensitivity in Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Double-Blind Clinical Trial 2017 · treatment group · Women with polycystic ovary syndrome (PCOS) | 1 g | 12 weeks | — |
| The effects of quercetin supplementation on metabolic and hormonal parameters as well as plasma concentration and gene expression of resistin in overweight or obese women with polycystic ovary syndrome 2018 · quercetin · Overweight or obese women aged 20–40 years with PCOS | 1 g | 12 weeks | — |
| Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial 2010 · Q-1000 · Men and women aged 18–85 from the community, including people with and without chronic disease | 1 g | 12 weeks | 333 |
| Prospective randomized trial evaluating blood and prostate tissue concentrations of green tea polyphenols and quercetin in men with prostate cancer 2020 · GT + Q · Men aged 43–74 with clinically localized prostate adenocarcinoma scheduled for radical prostatectomy | 800 mg | 4 weeks | 15 |
| Pharmacokinetics and bioavailability of quercetin glycosides in humans 2001 · quercetin-4'-O-glucoside · 12 healthy volunteers | 100 mg | 1 day | 12 |
| Higher plasma quercetin levels following oral administration of an onion skin extract compared with pure quercetin dihydrate in humans 2017 · onion skin extract powder · Healthy men and women aged 21–33 years | 163 mg | 1 day | 12 |
| Higher plasma quercetin levels following oral administration of an onion skin extract compared with pure quercetin dihydrate in humans 2017 · quercetin dihydrate · Healthy men and women aged 21–33 years | 134 mg | 1 day | 12 |
| Quercetin from shallots (Allium cepa L. var. aggregatum) is more bioavailable than its glucosides 2008 · shallot flesh · 9 volunteers; age, sex, and health status not specified | 1.4 mg/kg | 1 day | 9 |
| Quercetin from shallots (Allium cepa L. var. aggregatum) is more bioavailable than its glucosides 2008 · dry shallot skin · 9 volunteers; age, sex, and health status not specified | 1.4 mg/kg | 1 day | 9 |
| Dietary fat increases quercetin bioavailability in overweight adults 2013 · fat-free trial · Overweight or obese men and postmenopausal women at high risk for cardiovascular disease; mean age 55.9 years | 1.1 g | 1 day | 9 |
| Dietary fat increases quercetin bioavailability in overweight adults 2013 · low-fat trial · Overweight or obese men and postmenopausal women at high risk for cardiovascular disease; mean age 55.9 years | 1.1 g | 1 day | 9 |
| Dietary fat increases quercetin bioavailability in overweight adults 2013 · high-fat trial · Overweight or obese men and postmenopausal women at high risk for cardiovascular disease; mean age 55.9 years | 1.1 g | 1 day | 9 |
| Enriched cereal bars are more effective in increasing plasma quercetin compared with quercetin from powder-filled hard capsules 2012 · quercetin-enriched cereal bars · Healthy women aged 22–28 years | 130 mg | 1 day | 6 |
| Enriched cereal bars are more effective in increasing plasma quercetin compared with quercetin from powder-filled hard capsules 2012 · quercetin powder-filled hard capsules · Healthy women aged 22–28 years | 130 mg | 1 day | 6 |
| [Polyphenolic antioxidants in fruit juice. Urinary excretion and effects on biological markers for antioxidative status] 2000 · 750 mL juice dose · Five women and men; health status not stated | 4.8 mg | 7 days | 5 |
| [Polyphenolic antioxidants in fruit juice. Urinary excretion and effects on biological markers for antioxidative status] 2000 · 1000 mL juice dose · Five women and men; health status not stated | 6.4 mg | 7 days | 5 |
| [Polyphenolic antioxidants in fruit juice. Urinary excretion and effects on biological markers for antioxidative status] 2000 · 1500 mL juice dose · Five women and men; health status not stated | 9.6 mg | 7 days | 5 |
| Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans 2008 · Q50 · Healthy volunteers; age and sex not specified | 50 mg | 2 weeks | — |
| Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans 2008 · Q100 · Healthy volunteers; age and sex not specified | 100 mg | 2 weeks | — |
| Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans 2008 · Q150 · Healthy volunteers; age and sex not specified | 150 mg | 2 weeks | — |
| Effect of mixed flavonoids, n-3 fatty acids, and vitamin C on oxidative stress and antioxidant capacity before and after intense cycling 2011 · QC · Athletes; age and sex not specified | 1 g | 17 days | — |
| Supplementation of the Pure Flavonoids Epicatechin and Quercetin Affects Some Biomarkers of Endothelial Dysfunction and Inflammation in (Pre)Hypertensive Adults: A Randomized Double-Blind, Placebo-Controlled, Crossover Trial 2015 · quercetin · Apparently healthy (pre)hypertensive men and women aged 40–80 years | 160 mg | 4 weeks | 37 |
| Quercetin, but Not Epicatechin, Decreases Plasma Concentrations of Methylglyoxal in Adults in a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial with Pure Flavonoids 2018 · quercetin 3-glucoside · Apparently healthy, nonsmoking adults with systolic blood pressure between 125 and 160 mm Hg at screening | 160 mg | 4 weeks | 37 |
| Effect of quercetin on parameters of central hemodynamics and myocardial ischemia in patients with stable coronary heart disease 2017 · research group · Adults with stable coronary heart disease, stable angina pectoris, functional class II | 120 mg | 60 days | 30 |
| Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial 2024 · D + Q · Postmenopausal women aged 60–90 years with T-cell p16 mRNA expression above the 95th percentile of young female controls; generally healthy | 1 g | 20 weeks | 30 |
| Isoquercetin for thromboinflammation in sickle cell disease: a randomized double-blind placebo-controlled trial 2024 · IQ group · Adults aged 18 years or older with steady-state sickle cell disease | 1 g | 5 weeks | 23 |
| The flavonoid quercetin induces acute vasodilator effects in healthy volunteers: correlation with beta-glucuronidase activity 2014 · 200 mg quercetin · Healthy volunteers, mean age 26±5 years, including women and men | 200 mg | 1 day | 15 |
| Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers 2009 · quercetin phase · 12 healthy volunteers | 1.5 g | 7 days | 12 |
| Quercetin reduces markers of oxidative stress and inflammation in sarcoidosis 2011 · quercetin group · non-smoking, untreated patients with sarcoidosis; age and gender matched with the placebo group | 2 g | 1 day | 12 |
| Nonalcoholic red wine extract and quercetin inhibit LDL oxidation without affecting plasma antioxidant vitamin and carotenoid concentrations 2000 · quercetin group · male subjects; age and health condition not reported | 30 mg | 2 weeks | 10 |
| Effects of the flavonol quercetin and α-linolenic acid on n-3 PUFA status in metabolically healthy men and women: a randomised, double-blinded, placebo-controlled, crossover trial 2017 · ALA+quercetin · Metabolically healthy adult men and women | 190 mg | 8 weeks | — |
| Impact of multiple genetic polymorphisms on effects of a 4-week blueberry juice intervention on ex vivo induced lymphocytic DNA damage in human volunteers 2007 · blueberry/apple juice intervention · 168 healthy human volunteers; age and sex not reported | 97 mg | 4 weeks | 168 |
| Effect of mixed flavonoids, n-3 fatty acids, and vitamin C on oxidative stress and antioxidant capacity before and after intense cycling 2011 · QFO · Athletes; age and sex not specified | 1 g | 17 days | — |
| Dose-response to 3 months of quercetin-containing supplements on metabolite and quercetin conjugate profile in adults 2013 · Q-1000 · Healthy adults aged 40–83 years; women and men | 1 g | 90 days | — |
| Dose-response to 3 months of quercetin-containing supplements on metabolite and quercetin conjugate profile in adults 2013 · Q-500 · Healthy adults aged 40–83 years; women and men | 500 mg | 90 days | — |
| Enzymatically modified isoquercitrin in soy protein temporarily enhanced the plasma amino-acid concentrations, antioxidant index, and plasma hormone levels: a randomized, double-blind cross-over trial 2023 · Soy protein with 42 mg EMIQ · Nine healthy individuals; age range and sex not reported | 42 mg | 7 days | — |
| A Mixed Flavonoid-Fish Oil Supplement Induces Immune-Enhancing and Anti-Inflammatory Transcriptomic Changes in Adult Obese and Overweight Women-A Randomized Controlled Trial 2016 · Q-Mix · Women aged 40–70 years who were overweight or obese (BMI ≥25 kg/m²), without the listed major diseases | 500 mg | 10 weeks | 24 |
| Increased Plasma Levels of Gut-Derived Phenolics Linked to Walking and Running Following Two Weeks of Flavonoid Supplementation 2018 · flavonoid–walk · Healthy males and females aged 18–50 with a history of regular walking; no stated diagnosed condition | 104 mg | 2 weeks | 21 |
| Increased Plasma Levels of Gut-Derived Phenolics Linked to Walking and Running Following Two Weeks of Flavonoid Supplementation 2018 · flavonoid–sit · Healthy males and females aged 18–50 with a history of regular walking; no stated diagnosed condition | 104 mg | 2 weeks | 20 |